XRCC1 interactions with base excision repair DNA intermediates

Nazarkina, Zhanna K.; Ходырева, С. Н.; Marsin, Stéphanie; Lavrik, Olga I.; Radicella, J. Pablo

doi:10.1016/j.dnarep.2006.10.002

Cited by 93 publications

(56 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The possible explanation is that they enhance DNA repair capacity. XRCC1 gene is thought to be involved in DNA single-strand break repair, and also plays an important role in the BER pathway (Brem et al, 2005;Nazarkina et al, 2007). The gene polymorphism in codon 399 may be related to DNA repair, and likely has an effect on protein function (Savas et al, 2004).…”

Section: Discussionmentioning

confidence: 99%

XRCC1 and ADPRT Polymorphisms Associated with Survival in Breast Cancer Cases Treated with Chemotherapy

Rong¹,

Huang²,

Zheng³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

XRCC1 and ADPRT Polymorphisms Associated with Survival in Breast Cancer Cases Treated with Chemotherapy

Rong¹,

Huang²,

Zheng³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Soon thereafter, a stable complex of XRCC1 and LigIIIα was discovered [65] and by the late 1990s XRCC1 was established as a BER scaffold protein [66] in partnership with pol ß and PARP1 [16]. The list of cellular components that interact with XRCC1 has been expanded to include nicked DNA [67,68] and AP site containing DNA, both intermediates in the BER pathway [69]. In the past several years, XRCC1 coordination was further expanded to include pathway initiation enzymes (e.g.…”

Section: Scaffold Proteinsmentioning

confidence: 99%

A unified view of base excision repair: Lesion-dependent protein complexes regulated by post-translational modification

Almeida¹,

Sobol²

2007

DNA Repair

383

374

View full text Add to dashboard Cite

Base excision repair (BER) proteins act upon a significantly broad spectrum of DNA lesions that result from endogenous and exogenous sources. Multiple sub-pathways of BER (short-path or longpatch) and newly designated DNA repair pathways (e.g., SSBR and NIR) that utilize BER proteins complicate any comprehensive understanding of BER and its role in genome maintenance, chemotherapeutic response, neurodegeneration, cancer or aging. Herein, we propose a unified model of BER, comprised of three functional processes: Lesion Recognition/Strand Scission, Gap Tailoring and DNA Synthesis/Ligation, each represented by one or more multiprotein complexes and coordinated via the XRCC1/DNA Ligase III and PARP1 scaffold proteins. BER therefore may be represented by a series of repair complexes that assemble at the site of the DNA lesion and mediates repair in a coordinated fashion involving protein-protein interactions that dictate subsequent steps or sub-pathway choice. Complex formation is influenced by post-translational protein modifications that arise from the cellular state or the DNA damage response, providing an increase in specificity and efficiency to the BER pathway. In this review, we have summarized the reported BER proteinprotein interactions and protein post-translational modifications and discuss the impact on DNA repair capacity and complex formation.

show abstract

“…XRCC1 is thought to be involved in DNA single-strand break repair, 12 and it also plays an important role in the BER pathway. 13 An SNP in codon 399 was considered to be related to the DNA repair and was likely to exhibit an effect on the protein function. 14 Several studies have reported the association of XRCC1-399 with the risk in non-small-cell lung cancer (NSCLC), 15 colorectal cancer, 16 gastric cancer 17 and prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population

et al. 2007

View full text Add to dashboard Cite

Pharmacogenetic advances in cancer chemotherapy have the potential to predict clinical benefit to particular regimens. Platinum agents have shown to be effective in the treatment of gastric cancer. We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. SNPs of XPD-751, XRCC1-399 and GSTP1-105 in 62 gastric cancer patients were evaluated using the TaqMan 5 0 nuclease assay. Genotypes were correlated to survival. The median overall survival time was 322 days (range: 56-2058 days). The median survival times for patients with Arg/Arg or Arg/Gln genotypes of XRCC1 gene were significantly longer than others (P ¼ 0.03). For 58 patients with ECOG PS (Eastern Cooperative Oncology Group performance status)r2, more obvious significance was demonstrated (P ¼ 0.002). Patients with XRCC1-399 Gln/Gln genotype demonstrated a significant worse survival. No significant association was found between SNPs of XPD-751, GSTP1-105 and survival (P ¼ 0.125, 0.475, respectively). XRCC1 genotyping might make tailor chemotherapy possible for gastric cancer patients treated with oxaliplatin-based chemotherapy.

show abstract

XRCC1 interactions with base excision repair DNA intermediates

Cited by 93 publications

References 63 publications

XRCC1 and ADPRT Polymorphisms Associated with Survival in Breast Cancer Cases Treated with Chemotherapy

XRCC1 and ADPRT Polymorphisms Associated with Survival in Breast Cancer Cases Treated with Chemotherapy

A unified view of base excision repair: Lesion-dependent protein complexes regulated by post-translational modification

Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population

Contact Info

Product

Resources

About